Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of luspatercept in adults with congenital dyserythropoietic anemia type II
2020-005736-30Phase 2Terminated
- Sponsor
- Fondazione Foranemia
- Start
- Feb 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in Congenital Dyserythropoietic Anemia Type 2, sponsored by Fondazione Foranemia. Primary endpoint: Proportion of transfusion-dependent patients achieving any reduction of transfusion burden for at least 12 weeks during the treatment period. Started Feb 2023; status: terminated.
02
Drugs
luspatercept
03
Conditions
Congenital Dyserythropoietic Anemia Type 2
Beyond the preview
Go deeper on 2020-005736-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005736-30.